The future in your palm - a non-contact wearable...

How the 2026 U.S. tariff action on branded drugs...

COVID-19 has accelerated the shift in how pharma was engaging with HCPs, professional organisations and even patients in India from a sales to more of a scientific, unbiased and balanced marketing communications. As one of the business leader from a prominent MNC said, “For the first time we are seeing a certain shift in HCP’s preference for scientific communication for innovators companies. MSLs and scientific operation teams will be playing a key role in the near future.”

Q 1. Tell us about your journey as a pharma entrepreneur and what made you venture into pharma and stay on in pharma? My journey started with two good decisions, one- to be a Medical Representative (MR) in Mumbai, which built a strong foundation and the other, to join Helios, a new pharma company, which was like a baptism of fire. Together, they molded me well. I was promoted as a Front Line Manager (FLM) within a year. And after spending four excellent years in Helios, I joined Group Pharma as Product Manager (PM) and ever since, it’s been an exciting learning experience.  I was exposed to Pharma very early in life as my dad was in J L Morison, as part of the promoter-team of Warren Pharma. At home, I was the designated telephone operator and order processing clerk. Those were the days of trunk-calls - calling managers and distributors to note down orders. Hence, I was exposed to the excitement of targets, achievements, deficits and campaigns very early in my life. The idea of ‘work-life balance’ was not in vogue. One would look to their parents who worked long hours with pride making it something you wanted to emulate. Things have changed a lot but I would not trade the decision I made, to get into and stay in Pharma.

Smaller Indian pharma companies bore the strongest impact from...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...